Last week, the White House announced a 100% Section 232 tariff on large drones and critical components, citing their dual-use applications. The duties are set to take effect on September 3.
Aleris Corp, a Cleveland-based aluminum rolled products producer, announced its purchase by Zhongwang USA LLC on Monday. At $2.33 billion dollars, this is the United States’ largest overseas purchase of a metals processor.
The Barack Obama-Xi Jinping presidential bilateral meeting, slated for September 3 according to Chinese sources, will be the penultimate chance for the two leaders to meet during the Obama administration. Accompanied by Treasury Secretary Jack Lew and US Trade Representative Michael Froman, Obama is expected to discuss key issues in the US-China trade relationship with his Chinese counterpart before the G20 Summit.
We’ve curated the best of China Business Review into a traditional, easy-to-navigate magazine format. Don’t miss the innovative advertising opportunities to reach our well-informed audience.
The US-China Business Council has released the key findings of its 2016 annual member survey. For the past 11 years, USCBC has polled its members on their business performance in China and their priority issues.
Rick Doten, Chief of Cyber and Information Security at the Crumpton Group, answers questions about cybersecurity best practices for executives traveling to China. Doten states that executives must be aware that all communications will be monitored when they are in China, and makes suggestions for avoiding common mistakes and dealing with hacks if they do occur.
The China Certification of Information Security (CCIS) mark is required for all information security products used by the Chinese state agencies, and is voluntary for other information security products. China Compulsory Certification, or CCC, is required for many international products looking to enter the Chinese market; other factors, such as local requirements and potential uses of the device, could add the CCIS requirement, even for products not intended for government procurement.
New standards for the clinical and regulatory approval of foreign drugs and treatments in China’s pharmaceutical market are clouding revenue projections for multinational drugmakers, but they also represent an opportunity. A closer look at the regulatory challenges multinational pharmaceutical companies face can better position MNCs for long-term success in China’s fast-growing market for pharmaceuticals.
